[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100522888":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":45,"collaborators":47,"id":50,"slug":11,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":11,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":11,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":11,"overallStatus":29,"whyStopped":11,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Grit Biotechnology","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"TIL injection treatment group","EXPERIMENTAL",null,[13],"Biological: TIL injection",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"BIOLOGICAL","TIL injection","Autologous tumor infiltrating lymphocyte injection",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Zhengxiang Han, PHD","CONTACT","+86 18052268612","cnhzxyq@163.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"The Affiliated Hospital of Xuzhou Medical University","RECRUITING","Xuzhou","Jiangsu","221000","China",{"type":35,"coordinates":36},"Point",[37,38],117.28386,34.20442,{"lat":38,"lon":37},[41,42],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},{"name":43,"role":44,"phone":11,"phoneExt":11,"email":11},"Zhengxiang Han","PRINCIPAL_INVESTIGATOR",{"type":46,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[48],{"name":28,"class":49},"OTHER","100522888",false,"NCT06088472","TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors","A Single-arm Phase I Clinical Study of TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors","Inclusion Criteria:\n\n* 1\\. Voluntarily participate in the study, sign the informed consent form, and be willing and able to follow the study protocol ;\n* 2.Must have a confirmed diagnosis of malignancy of their receptive histologies or cytologies: unresectable recurrent or metastatic solid tumor;\n* 3.At least one resectable lesion (preferably superficial metastatic lymph nodes) that has not been treated with radiation and has not received other local therapies, and at least tissue blocks with a volume of≥0.5 cubic centimeter (either of single lesion origin or multiple lesions combined) can be isolated for the preparation of autologous tumor-infiltrating lymphocytes. Minimally invasive treatment where possible;\n\nExclusion Criteria:\n\n* 1\\. Patients who have symptomatic and\u002For untreated CNS metastases (Except stable brain metastases, no medication required within 3 months, no hormone dependence);\n* 2.The patient who has any active autoimmune disease, history of autoimmune disease, need for systemic steroid hormones or a condition requiring immunosuppressive drug therapy (\\>10 mg\u002Fday of prednisone or equivalent hormone) within 14 days before lymphocyte depletion chemotherapy;\n* 3\\. Arterial\u002Fvenous thrombotic events within 6 months prior to enrollment, such as: cerebrovascular accident, deep vein thrombosis and pulmonary embolism occurring;\n* 4.Active infections requiring treatment with systemic anti-infectives (except for topical antibiotics); or those with unexplained fever \\> 38.5℃ occurring during the screening period, except for tumor fever;\n* 5\\. Patients who have refractory or intractable epilepsy, hydrops abdominis, active gastrointestinal bleeding or IL-2 contraindications;\n* 6\\. Patients who have received allogeneic bone marrow transplantation or an organ allograft;\n* 7.Patients who have a history of hypersensitivity to any component or excipient of study drugs: autologous tumor infiltrating lymphocytes, cyclophosphamide, fludarabine, IL-2, dimethyl sulfoxide (DMSO), human serum albumin (HSA), dextran-40 and antibiotics (beta lactam antibiotics, gentamicin);","ALL","18 Years","70 Years",{"count":60,"type":61},12,"ESTIMATED","INTERVENTIONAL",[64],"PHASE1","This is a single-center, single-arm phase I clinical trial.The study process was divided into: screening period, sampling and production period, NMA-LD chemotherapy , treatment and observation period, and follow-up period.",[67],"Solid Tumors, Adult","2025-09-23",{"date":70,"type":71},"2025-09-29","ACTUAL",{"date":73,"type":71},"2021-04-21",{"date":75,"type":61},"2027-12-31",{"name":5,"class":6},1]